

-4- (Fourth amended)

A composition comprising an isolated 16 ( $\pm 4$ ) kDa *Sarcocystis neurona* antigen and an isolated 30 ( $\pm 4$ ) kDa *Sarcocystis neurona* antigen in a pharmaceutically accepted carrier.

-13- (Twice amended)

A method for treating an equine with a *Sarcocystis neurona* infection comprising:

(a) providing a composition consisting essentially of an isolated 16 ( $\pm 4$ ) kDa antigen and an isolated 30 ( $\pm 4$ ) kDa antigen of *Sarcocystis neurona* in a pharmaceutically accepted carrier; and

(b) inoculating the equine with the composition to treat the equine with the *Sarcocystis neurona* infection.

-45- (Twice amended)

A method for treating a disease in an equine caused by a *Sarcocystis neurona* infection which comprises providing a composition which when injected into the equine causes the equine to produce antibodies against a 16 ( $\pm 4$ ) kDa antigen and a 30 ( $\pm 4$ ) kDa antigen of the *Sarcocystis neurona* which treats the disease caused by the *Sarcocystis neurona*.

-46- (Amended)

The method of Claim 45 wherein the composition comprises an isolated 16 ( $\pm 4$ ) kDa antigen and an isolated 30 ( $\pm 4$ ) kDa antigen in a pharmaceutically accepted carrier.

-50- (Amended)

The method of Claim 45 wherein the composition is administered by an inoculation route selected from the group consisting of intranasal administration, intramuscular injection, intraperitoneal injection,  
5 intradermal injection, and subcutaneous injection.